Key facts at a glance
In 2013, actor and filmmaker Angelina Jolie underwent a bilateral (double) mastectomy after genetic testing showed a pathogenic BRCA1 mutation that elevated her risk of breast cancer. The procedures were elective and preventive rather than cancer treatment at that time. This overview explains what a double mastectomy involves, why someone with a BRCA mutation may choose this approach, typical outcomes and risks, and how such decisions affect screening and long-term health planning.
- What happened: preventive bilateral mastectomy to reduce high genetic risk
- Why it mattered: public discussion of genetic testing, risk management, and surgical options
- Evergreen context: how this case informs conversations about risk, screening, and prevention
What is a double mastectomy
A double (or bilateral) mastectomy is the surgical removal of both breasts. It differs from a single mastectomy in that both glandular and fatty tissue are typically removed, although the nipple-areola complex may be preserved in some approaches (nipple-sparing mastectomy). Types include:
- Simple (total) mastectomy: removal of breast tissue, skin, and nipple
- Skin-sparing mastectomy: removal of breast tissue and nipple with preservation of most skin
- Nipple-sparing mastectomy: removal of breast tissue while keeping the nipple and areola
Reconstruction can occur at the same time (immediate) or in a later procedure (delayed). A double mastectomy aims to remove most breast tissue to lower the risk of developing cancer in either breast.
Why Angelina Jolie chose a double mastectomy
In a 2013 New York Times op-ed, Jolie wrote that she had a deleterious mutation in the BRCA1 gene, which significantly raises the lifetime risk of breast and ovarian cancers. Her doctors estimated she had around an 87% lifetime risk of breast cancer based on family history and genetic testing. She opted for a preventive double mastectomy to reduce that risk. This decision was driven by a combination of personal risk factors, family history, and the availability of genetic testing that can identify high-risk mutations before cancer develops.
What BRCA1 mutations mean
BRCA1 and BRCA2 are tumor-suppressor genes that help repair damaged DNA. Harmful mutations can impair that repair function, increasing the lifetime risk of breast and ovarian cancers. In people with a BRCA1 mutation, the estimated lifetime risk of breast cancer is approximately 55–72%, and the risk of ovarian cancer is approximately 39–44%. These ranges vary by study, ancestry, and other factors; not everyone with a BRCA1 mutation will develop cancer, but the probability is substantially higher than in the general population.
Medical context and surgical details
A preventive double mastectomy is an elective procedure intended to lower cancer risk rather than treat existing cancer. Typical steps and considerations include:
- Preoperative genetic counseling and testing to confirm a mutation such as BRCA1 or BRCA2
- Discussion of surgical options, including skin-sparing or nipple-sparing techniques
- Anesthesia, removal of breast tissue, and, if chosen, immediate reconstruction
- Pathology examination of removed tissue to confirm complete removal and absence of occult cancer
- Ongoing surveillance for the remaining chest wall and possible late effects of reconstruction
Outcomes, risks, and long-term considerations
For people with a high-risk BRCA mutation, bilateral mastectomy can substantially reduce the risk of breast cancer. Studies report risk reductions of approximately 90% or more after removal of most breast tissue. However, the procedure carries typical surgical risks, including infection, bleeding, poor wound healing, and anesthesia-related complications. Long-term considerations include changes in sensation, possible need for further surgeries, and the importance of ongoing follow-up to monitor for recurrence (if cancer was present at the time) and to address new or unrelated breast changes.
Comparative risk reduction approaches
Some individuals with a BRCA mutation choose alternatives to mastectomy, including:
- Enhanced screening (more frequent mammography and MRI)
- Risk-reducing medications (chemoprevention)
- Risk-reducing salpingo-oophorectomy (removal of ovaries and fallopian tubes) to lower ovarian cancer risk, often after child completion
The best approach depends on personal risk, age, family planning, and medical guidance.
Impact on screening and reconstruction
After a double mastectomy with reconstruction, mammography is typically no longer performed on breast tissue because most breast tissue has been removed. However, imaging of the chest wall may still be recommended in certain situations. Reconstruction options and timing influence follow-up plans, and decisions about additional risk-reducing surgeries (such as removing the ovaries) are often coordinated with a multidisciplinary team that may include surgeons, oncologists, and genetic counselors.
Broader implications and public discourse
Jolie’s public disclosure helped elevate conversations about genetic risk, patient choice, and preventive options. It also highlighted the importance of genetic counseling in helping people understand what a BRCA mutation means for their health and the range of reasonable management strategies. The case does not dictate what others should do, but it underscores how personal decisions about risk can inform broader awareness of options in hereditary cancer prevention.
Frequently asked questions
| Question | Answer | Notes |
|---|---|---|
| Does a double mastectomy remove all breast cancer risk? | No, but it substantially lowers it. Some risk remains in residual tissue or chest wall. | Not absolute prevention |
| Can men with BRCA mutations benefit from risk-reducing mastectomy? | Yes, though their lifetime breast cancer risk is lower than for women; decisions are individualized. | Option is available and evidence-based |
| Is immediate reconstruction always possible? | It depends on anatomy, cancer risk, and personal choice; not every case is suitable for immediate reconstruction. | Surgical and medical factors apply |
Evergreen takeaways
Angelina Jolie’s 2013 double mastectomy remains a reference point for understanding how genetic risk can shape prevention strategies. The case illustrates the value of genetic testing and counseling, the range of surgical and non-surgical options for managing high risk, and the importance of individualized decision-making with a specialized care team. These points retain relevance as screening guidelines, reconstructive techniques, and hereditary cancer research continue to evolve.
Summary
Angelina Jolie’s preventive double mastectomy was undertaken to lower a very high genetic risk of breast cancer identified through BRCA1 testing. It is one option among several for risk management and is not automatically appropriate for everyone with elevated risk. Outcomes are generally favorable in risk reduction, though the procedure carries known surgical risks and long-term considerations. The ongoing importance of genetic counseling, personalized screening, and informed decision-making applies to many people at hereditary cancer risk, regardless of whether they pursue mastectomy.
Additional resources and next steps
People concerned about genetic risk or prevention strategies are encouraged to meet with a genetic counselor and a multidisciplinary cancer care team. Resources such as reputable cancer centers and hereditary cancer programs can provide guidance on testing, risk assessment, and tailored surveillance or prevention plans.
Tags
BRCA, genetic testing, mastectomy, prevention